Last edition
News about "Phase 2/3 clinical trial"
Johnson & Johnson Secures FDA Priority Review for Imaavy in Rare Blood Disorder
Johnson & Johnson moves closer to delivering a first-in-class treatment for Warm Autoimmune Haemolytic Anaemia with FDA Priority Review for Imaavy.
Phase 2/3 Clinical Trial | 28/04/2026 | By News Bureau
Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status
Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.
Phase 2/3 Clinical Trial | 27/04/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy